Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP

Lewis, Jada, Dickson, Dennis W., Lin, Wen-Lang, Chisholm, Louise, Corral, Anthony, Jones, Graham, Yen, Shu-Hui, Sahara, Naruhiko +6 more·2001·Science
DOI 10.1126/science.1058189

Cited by (167)

Items 101–167 of 167

  1. Human secreted tau increases amyloid-beta production
    Bright, Jessica, Hussain, Sami, Dang, Vu, Wright, Sarah, Cooper, Bonnie, Byun, Tony, Ramos, Carla, Singh, Andrew, Parry, Graham, Stagliano, Nancy et al. · 2015 · Neurobiology of Aging
  2. Sex and Gender Differences in Alzheimer's Disease: Recommendations for Future Research
    Carter, Christine L., Resnick, Eileen M., Mallampalli, Monica, Kalbarczyk, Anna · 2012 · Journal of Women's Health
  3. Immunotherapy for Alzheimer’s disease: Key Symposium: Immunotherapy for Alzheimer’s disease
    Morgan, D. · 2011 · Journal of Internal Medicine
  4. Aβ accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model
    Hurtado, David E., Molina-Porcel, Laura, Iba, Michiyo, Aboagye, Awo K., Paul, Steven M., Trojanowski, John Q., Lee, Virginia M.-Y. · 2010 · The American Journal of Pathology
  5. Soluble Aβ Oligomers Are Rapidly Sequestered from Brain ISF In Vivo and Bind GM1 Ganglioside on Cellular Membranes
    Hong, Soyon, Ostaszewski, Beth L., Yang, Ting, O’Malley, Tiernan T., Jin, Ming, Yanagisawa, Katsuhiko, Li, Shaomin, Bartels, Tim, Selkoe, Dennis J. · 2014 · Neuron
  6. Fluid Biomarkers in Alzheimer Disease
    Blennow, K., Zetterberg, H., Fagan, A. M. · 2012 · Cold Spring Harbor Perspectives in Medicine
  7. The Role of Caspase Cleavage of Tau in Alzheimer Disease Neuropathology
    Cotman, Carl W., Poon, Wayne W., Rissman, Robert A., Blurton-Jones, Mathew · 2005 · Journal of Neuropathology & Experimental Neurology
  8. <scp> <i>APOE</i> </scp> ε2 is associated with milder clinical and pathological <scp>A</scp> lzheimer disease
    Serrano‐Pozo, Alberto, Qian, Jing, Monsell, Sarah E., Betensky, Rebecca A., Hyman, Bradley T. · 2015 · Annals of Neurology
  9. Transgenic mouse models of alzheimer disease: Developing a better model as a tool for therapeutic interventions.
    Kitazawa, Masashi, Medeiros, Rodrigo, M. LaFerla, Frank · 2012 · Current Pharmaceutical Design
  10. Tau protein and neurodegeneration
    Goedert, Michel · 2004 · Seminars in Cell &amp; Developmental Biology
  11. Galantamine-induced Amyloid-β Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors
    Takata, Kazuyuki, Kitamura, Yoshihisa, Saeki, Mana, Terada, Maki, Kagitani, Sachiko, Kitamura, Risa, Fujikawa, Yasuhiro, Maelicke, Alfred, Tomimoto, Hidekazu, Taniguchi, Takashi et al. · 2010 · Journal of Biological Chemistry
  12. Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia
    Ferrer, Isidro · 2012 · Progress in Neurobiology
  13. Molecular Genetics of Late‐Onset Alzheimer's Disease
    Kamboh, M. Ilyas · 2004 · Annals of Human Genetics
  14. Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats
    Sun, L, Liu, S.Y, Zhou, X.W, Wang, X.C, Liu, R, Wang, Q, Wang, J.Z · 2003 · Neuroscience
  15. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice
    Ribé, Elena M., Pérez, Mar, Puig, Berta, Gich, Ignasi, Lim, Filip, Cuadrado, Mar, Sesma, Teresa, Catena, Silvia, Sánchez, Belén, Nieto, María et al. · 2005 · Neurobiology of Disease
  16. Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats
    Wen, Yi, Yang, Shao-Hua, Liu, Ran, Perez, Evelyn J., Brun-Zinkernagel, Anne Marie, Koulen, Peter, Simpkins, James W. · 2007 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  17. Accumulation of tau induced in neurites by microglial proinflammatory mediators
    Gorlovoy, Philipp, Larionov, Sergey, Pham, Thao Thi Hien, Neumann, Harald · 2009 · The FASEB Journal
  18. Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials
    Basheer, Neha, Smolek, Tomáš, Hassan, Imtaiyaz, Liu, Fei, Iqbal, Khalid, Zilka, Norbert, Novak, Petr · 2023 · Molecular Psychiatry
  19. Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer’s disease
    Kwak, Sang Su, Washicosky, Kevin J., Brand, Emma, von Maydell, Djuna, Aronson, Jenna, Kim, Susan, Capen, Diane E., Cetinbas, Murat, Sadreyev, Ruslan, Ning, Shen et al. · 2020 · Nature Communications
  20. Co-occurrence of Alzheimer's disease β-amyloid and tau pathologies at synapses
    Takahashi, Reisuke H., Capetillo-Zarate, Estibaliz, Lin, Michael T., Milner, Teresa A., Gouras, Gunnar K. · 2010 · Neurobiology of Aging
  21. Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease
    Bhattacharya, Soumee, Haertel, Christin, Maelicke, Alfred, Montag, Dirk · 2014 · PLoS ONE
  22. Biochemistry and Molecular Biology of Amyloid β‐Protein and the Mechanism of Alzheimer's Disease
    2008 · Handbook of Clinical Neurology
  23. Parenchymal and vascular Aβ‐deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease
    Thal, Dietmar Rudolf, Griffin, W. Sue T., Braak, Heiko · 2008 · Journal of Cellular and Molecular Medicine
  24. Communication breaks-Down: From neurodevelopment defects to cognitive disabilities in Down syndrome
    Contestabile, Andrea, Benfenati, Fabio, Gasparini, Laura · 2010 · Progress in Neurobiology
  25. Down-regulation of WW Domain-containing Oxidoreductase Induces Tau Phosphorylation in Vitro
    Sze, Chun-I, Su, Meng, Pugazhenthi, Subbiah, Jambal, Purevsuren, Hsu, Li-Jin, Heath, John, Schultz, Lori, Chang, Nan-Shan · 2004 · Journal of Biological Chemistry
  26. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain
    Arendash, Gary W, Lewis, Jada, Leighty, Ralph E, McGowan, Eileen, Cracchiolo, Jennifer R, Hutton, Mike, Garcia, Marcos F · 2004 · Brain Research
  27. Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology
    Liu, R., Zhou, X.‐W., Tanila, H., Bjorkdahl, C., Wang, J.‐Z., Guan, Z.‐Z., Cao, Y., Gustafsson, J.‐Å., Winblad, B., Pei, J.‐J. · 2008 · Journal of Cellular and Molecular Medicine
  28. Accumulation of Filamentous Tau in the Cerebral Cortex of Human Tau R406W Transgenic Mice
    Ikeda, Masaki, Kawarai, Toshitaka, Kawarabayashi, Takeshi, Matsubara, Etsuro, Murakami, Tetsuro, Sasaki, Atsushi, Tomidokoro, Yasushi, Ikarashi, Yasushi, Kuribara, Hisashi, Ishiguro, Koichi et al. · 2005 · The American Journal of Pathology
  29. Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
    Golde, Todd E. · 2022 · Neurotherapeutics
  30. Disease modifying therapy for AD?<sup>1</sup>
    Golde, Todd E. · 2006 · Journal of Neurochemistry
  31. Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies
    Sigurdsson, Einar M. · 2008 · Journal of Alzheimer's Disease
  32. Phosphorylation of Tau at S422 is enhanced by Aβ in TauPS2APP triple transgenic mice
    Grueninger, Fiona, Bohrmann, Bernd, Czech, Christian, Ballard, Theresa Maria, Frey, Johann R., Weidensteiner, Claudia, von Kienlin, Markus, Ozmen, Laurence · 2010 · Neurobiology of Disease
  33. Delineating the Mechanism of Alzheimer’s Disease Aβ Peptide Neurotoxicity
    Cappai, Roberto, Barnham, Kevin J. · 2008 · Neurochemical Research
  34. Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo
    DeVos, Sarah L, Corjuc, Bianca T, Commins, Caitlin, Dujardin, Simon, Bannon, Riley N, Corjuc, Diana, Moore, Benjamin D, Bennett, Rachel E, Jorfi, Mehdi, Gonzales, Jose A et al. · 2018 · Brain
  35. Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity
    Ando, Kanae, Maruko-Otake, Akiko, Ohtake, Yosuke, Hayashishita, Motoki, Sekiya, Michiko, Iijima, Koichi M. · 2016 · PLOS Genetics
  36. Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
    Fedele, Ernesto · 2023 · International Journal of Molecular Sciences
  37. Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Aβ(1-42): Implications for Alzheimer’s Disease
    Boyd-Kimball, Debra, Poon, H. Fai, Lynn, Bert C., Cai, Jian, Pierce Jr., William M., Klein, Jon B., Ferguson, Jmil, Link, Christopher D., Butterfield, D. Allan · 2006 · Neurobiology of Aging
  38. In Vivo Pharmacological Characterization of a Novel Selective α7 Neuronal Nicotinic Acetylcholine Receptor Agonist ABT-107: Preclinical Considerations in Alzheimer's Disease
    Bitner, R. Scott, Bunnelle, William H., Decker, Michael W., Drescher, Karla U., Kohlhaas, Kathy L., Markosyan, Stella, Marsh, Kennan C., Nikkel, Arthur L., Browman, Kaitlin, Radek, Rich et al. · 2010 · The Journal of Pharmacology and Experimental Therapeutics
  39. Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer's disease
    Chabrier, Meredith A., Cheng, David, Castello, Nicholas A., Green, Kim N., LaFerla, Frank M. · 2014 · Neurobiology of Disease
  40. CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer’s Disease
    Shentu, Yang-Ping, Huo, Yuda, Feng, Xiao-Long, Gilbert, James, Zhang, Qing, Liuyang, Zhen-Yu, Wang, Xiu-Lian, Wang, Guan, Zhou, Huan, Wang, Xiao-Chuan et al. · 2018 · Cell Reports
  41. Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
    Buccellato, Francesca R., D’Anca, Marianna, Tartaglia, Gianluca Martino, Del Fabbro, Massimo, Scarpini, Elio, Galimberti, Daniela · 2023 · International Journal of Molecular Sciences
  42. A potential role for alterations of zinc and zinc transport proteins in the progression of Alzheimer's disease
    Lovell, Mark A. · 2009 · Journal of Alzheimer s Disease
  43. Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer’s disease
    Saul, Anika, Sprenger, Frederik, Bayer, Thomas A., Wirths, Oliver · 2013 · Neurobiology of Aging
  44. Increased misfolding and truncation of tau in APP/PS1/tau transgenic mice compared to mutant tau mice
    Héraud, Céline, Goufak, Doris, Ando, Kunie, Leroy, Karelle, Suain, Valérie, Yilmaz, Zehra, De Decker, Robert, Authelet, Michèle, Laporte, Vincent, Octave, Jean-Noël et al. · 2014 · Neurobiology of Disease
  45. Activation of PAR-1 Kinase and Stimulation of Tau Phosphorylation by Diverse Signals Require the Tumor Suppressor Protein LKB1
    Wang, Ji-Wu, Imai, Yuzuru, Lu, Bingwei · 2007 · The Journal of Neuroscience
  46. Drugs targeting alzheimer’s disease: Some things old and some things new
    Michaelis, Mary L. · 2003 · The Journal of Pharmacology and Experimental Therapeutics
  47. The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1
    Ciccone, Lidia, Shi, Chenghui, di Lorenzo, Davide, Van Baelen, Anne-Cécile, Tonali, Nicolo · 2020 · Molecules
  48. Cross Currents in Protein Misfolding Disorders: Interactions and Therapy
    Morales, Rodrigo, Green, Kristi, Soto, Claudio · 2009 · CNS &amp; Neurological Disorders - Drug Targets
  49. Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of Aβ42 and Alzheimer’s disease neuropathology
    Hashimoto, Masakazu, Bogdanovic, Nenad, Volkmann, Inga, Aoki, Mikio, Winblad, Bengt, Tjernberg, Lars O. · 2010 · Acta Neuropathologica
  50. Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer’s disease
    Aucoin, J.-S., Jiang, P., Aznavour, N., Tong, X.-K., Buttini, M., Descarries, L., Hamel, E. · 2005 · Neuroscience
  51. Tau acts as a mediator for<scp>A</scp>lzheimer's disease‐related synaptic deficits
    Liao, Dezhi, Miller, Eric C., Teravskis, Peter J. · 2014 · European Journal of Neuroscience
  52. γ-Secretase and its modulators: Twenty years and beyond
    Xia, Weiming · 2019 · Neuroscience Letters
  53. Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies
    Bittar, Alice, Sengupta, Urmi, Kayed, Rakez · 2018 · npj Vaccines
  54. Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets
    Pei, Jin-Jing, Sjögren, Magnus, Winblad, Bengt · 2008 · Current Opinion in Psychiatry
  55. Expression of Tau40 Induces Activation of Cultured Rat Microglial Cells
    Wang, Lu, Jiang, Qian, Chu, Jiang, Lin, Li, Li, Xiao-Guang, Chai, Gao-Shang, Wang, Qun, Wang, Jian-Zhi, Tian, Qing · 2013 · PLoS ONE
  56. Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer’s disease
    Stancu, Ilie‐Cosmin, Ris, Laurence, Vasconcelos, Bruno, Marinangeli, Claudia, Goeminne, Léonie, Laporte, Vincent, Haylani, Laetitia E., Couturier, Julien, Schakman, Olivier, Gailly, Philippe et al. · 2014 · The FASEB Journal
  57. Insights on the Use of Transgenic Mice Models in Alzheimer’s Disease Research
    Pádua, Mafalda Soares, Guil-Guerrero, José L., Prates, José A. M., Lopes, Paula Alexandra · 2024 · International Journal of Molecular Sciences
  58. Selective vulnerability of different types of commissural neurons for amyloid  -protein-induced neurodegeneration in APP23 mice correlates with dendritic tree morphology
    Capetillo-Zarate, E., Staufenbiel, M., Abramowski, D., Haass, C., Escher, A., Stadelmann, C., Yamaguchi, H., Wiestler, O. D., Thal, D. R. · 2006 · Brain
  59. Hyperphosphorylated tau is a cause of neuronal dysfunction in tauopathy
    Takashima, Akihiko · 2008 · Journal of Alzheimer s Disease
  60. Spatial memory deficiency early in 6xTg Alzheimer’s disease mouse model
    Kang, Shinwoo, Kim, Jinho, Chang, Keun-A · 2021 · Scientific Reports
  61. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models
    Hannan, Shabab B., Dräger, Nina M., Rasse, Tobias M., Voigt, Aaron, Jahn, Thomas R. · 2016 · Journal of Neurochemistry
  62. Integrated biology approach reveals molecular and pathological interactions among Alzheimer’s Aβ42, Tau, TREM2, and TYROBP in Drosophila models
    Sekiya, Michiko, Wang, Minghui, Fujisaki, Naoki, Sakakibara, Yasufumi, Quan, Xiuming, Ehrlich, Michelle E., De Jager, Philip L., Bennett, David A., Schadt, Eric E., Gandy, Sam et al. · 2018 · Genome Medicine
  63. Aβ treatment and P301L tau expression in an Alzheimer's disease tissue culture model act synergistically to promote aberrant cell cycle re‐entry
    Hoerndli, Frederic J., Pelech, Steven, Papassotiropoulos, Andreas, Götz, Jürgen · 2007 · European Journal of Neuroscience
  64. Combinatorial model of amyloid β and tau reveals synergy between amyloid deposits and tangle formation
    Koller, Emily J., Ibanez, Kristen R., Vo, Quan, McFarland, Karen N., Gonzalez De La Cruz, Elsa, Zobel, Lillian, Williams, Tristan, Xu, Guilian, Ryu, Daniel, Patel, Preya et al. · 2022 · Neuropathology and Applied Neurobiology
  65. Alzheimer’s Disease: Dawn of a New Era?
    Amirrad, Farideh, Bousoik, Emira, Shamloo, Kiumars, Al-Shiyab, Hassan, Nguyen, Viet-Huong V., Montazeri Aliabadi, Hamidreza · 2017 · Journal of Pharmacy &amp; Pharmaceutical Sciences
  66. Increase in Tau Pathology in P290S <i>Mapt</i> Knock-In Mice Crossed with <i>App</i> <sup>NL-G-F</sup> Mice
    Huang, Melissa, Macdonald, Jennifer, Lavenir, Isabelle, Chen, Renren, Craxton, Molly, Slavik-Smith, Elizabeth, Davies, Stephen W., Goedert, Michel · 2022 · eneuro
  67. Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau
    Zampar, Silvia, Wirths, Oliver · 2021 · International Journal of Molecular Sciences